Citations

Clear

1053 citation(s) found for "Andre, F".

The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome
Mohr, Sandra , Fritz, Nikola, Hammer, Christian , Martínez, Cristina , Berens, Sabrina , Schmitteckert, Stefanie , Wahl, Verena, Schmidt, Målin , Houghton, Lesley A. , Goebel‐Stengel, Miriam , Kabisch, Maria, Götze, Dorothea, Milovač, Irina , D’Amato, Mauro , Röth, Ralph , Mönnikes, Hubert, Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Pehl, Christian, Stein‐Thöringer, Christoph, Clarke, Gerard , Kennedy, Paul J. , Cryan, John F. , Spiller, Robert E. , Beltrán, Caroll J. , Madrid, Ana María , Torres, Verónica , Arce, Edith Pérez de , Herzog, Wolfgang , Sayuk, Gregory S. , Karamanolis, George, Pojskić, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier, Wouters, Mira M. , Rappold, Gudrun , Santos, Javier , Schaefert, Rainer , Niesler, Beate , Zheng, Tenghao , Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Keller, Jutta , Stein-Thöringer, Christoph , Clarke, Gerard , Kennedy, Paul J , Cryan, John F , Dinan, Timothy G , Quigley, Eamonn M M , Spiller, Robin , Madrid, Ana María , Pérez de Arce, Edith , Herzog, Wolfgang , Mayer, Emeran A , Sayuk, Gregory , Gazouli, Maria , Karamanolis, George , Kapur-Pojskič, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier , Franke, André , Lieb, Wolfgang , Boeckxstaens, Guy , Wouters, Mira M , Simrén, Magnus , Rappold, Gudrun A , Vicario, Maria , Santos, Javier , Schaefert, Rainer , Lorenzo-Bermejo, Justo , Niesler, Beate , D'Amato, Mauro , Houghton, L A , Martínez, Cristina , Zheng, Tenghao , Stein-Thöringer, Christoph K., Quigley, Eamonn M.M. , Torres, Verónica, Boeckxstaens, Guy E. , Simrén, Magnus , Bermejo, Justo Lorenzo

Mayo Clinic

Journal of Cellular and Molecular Medicine | June 24, 2021 | Volume: 25 | Issue: 16 | Pages: 8047-8061

10.1111/jcmm.16736 | PMID 34165249 Get It

AbstractIrritable bowel syndrome (IBS) is a gut‐brain disorder in which symptoms are shaped by serotonin acting centrally and peripherally. The serotonin transporter gene SLC6A4 has been implicated in IBS pathophysiology, but the underlying genetic mechanisms remain unclear. We sequenced the alternative P2 promoter driving intestinal SLC6A4 expression and identified single nucleotide polymorphisms (SNPs) that were associated with IBS in a discovery sample. Identified SNPs built different haplotypes, and the tagging SNP rs2020938 seems to associate with constipation‐predominant IBS (IBS‐C) in females. rs2020938 validation was performed in 1978 additional IBS patients and 6,038 controls from eight countries. Meta‐analysis on data from 2,175 IBS patients and 6,128 controls confirmed the association with female IBS‐C. Expression analyses revealed that the P2 promoter drives SLC6A4 expression primarily in the small intestine. Gene reporter assays showed a functional impact of SNPs in the P2 region. In silico analysis of the polymorphic promoter indicated differential expression regulation. Further follow‐up revealed that the major allele of the tagging SNP rs2020938 correlates with differential SLC6A4 expression in the jejunum and with stool consistency, indicating functional relevance. Our data consolidate rs2020938 as a functional SNP associated with IBS‐C risk in females, underlining the relevance of SLC6A4 in IBS pathogenesis.
Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells
Walter, Karolin , Rodríguez-Aznar, Eva , Ferreira, Mónica S. Ventura , Frappart, Pierre‐Olivier , Dittrich, Tabea, Tiwary, Kanishka , Meessen, Sabine, Lerma, Laura , Daiß, Nora, Schulte, Lucas-Alexander , Najafova, Zeynab , Arnold, Frank , Usachov, Valentyn , Azoitei, Ninel , Erkan, Mert , Brümmendorf, Tim H. , Seufferlein, Thomas , Kleger, Alexander , Tabarés, E. , Güneş, Çagatay , Johnsen, Steven A. , Beier, Fabian , Sáinz, Bruno , Hermann, Patrick , Brümmendorf, Tim H , Kleger, Alexander , Günes, Cagatay , Johnsen, Steven A , Beier, Fabian , Sainz, Bruno , Hermann, Patrick C , Najafova, Zeynab , Lechel, André

Mayo Clinic

Cancers | June 23, 2021 | Volume: 13 | Issue: 13 | Pages: 3145

10.3390/cancers13133145 | PMID 34201898 Get It

To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the “stemness” maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients.
Metabolic Syndrome Blunts the Capacity of Mesenchymal Stem Cell‐Derived Extracellular Vesicles to Preserve the Post‐Stenotic Kidney in Swine Renal Artery Stenosis
Zhu, Xiangyang , Jordan, Kyra L., Lerman, Lilach O. , Eirin, Alfonso , Lerman, Amir , Wijnen, André J. van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.835.8 Get It

Background Mesenchymal stem/stromal cells (MSCs) release extracellular vesicles (EVs), which shuttle proteins to recipient cells, promoting cellular repair. We hypothesized that cardiovascular risk factors may alter the pattern of proteins packed within MSC‐derived EVs, blunting their capacity to preserve the post‐stenotic kidney in pigs with metabolic syndrome (MetS) and renal artery stenosis (RAS). Methods We compared the protein cargo of EVs to their parent MSCs obtained from pigs with MetS and Lean controls. Porcine MSCs were harvested from abdominal fat after 16 weeks of Lean‐ or MetS‐diet (n=5 each), and their EVs isolated. Following LC‐MS/MS proteomics, clustering analysis was performed to identify primary functional categories of proteins enriched in Lean‐ and MetS‐EVs. In addition, MetS pigs were studied after 16 weeks of RAS untreated or treated 4 weeks earlier with a single intrarenal delivery of allogeneic labeled Lean‐ or MetS‐EVs (2.5x10^5/Kg). Lean and MetS Sham served as controls (n=6 each). Single‐kidney volume, renal blood flow (RBF), and glomerular filtration rate (GFR) were studied in‐vivo (multi‐detector CT), and tubular injury (Periodic Acid Schiff) and fibrosis (Trichrome) ex‐vivo. Results Proteomics analysis identified 6,690 and 6,790 distinct proteins in Lean‐ and MetS‐EVs, respectively. Differential expression analysis revealed that 91 proteins were upregulated in Lean‐EVs and 130 proteins in MetS‐EVs compared to their parent MSCs (FDR<0.05 and log2 fold‐change EVs/MSCs>2). Proteins enriched exclusively in Lean‐EVs modulate pathways related to the MSC reparative capacity, including cell proliferation, differentiation, and activation, as well as transforming growth factor‐β signaling (Figure 1A). Contrarily, proteins enriched only in MetS‐EVs are linked to pro‐inflammatory pathways, including acute inflammatory response, leukocyte transendothelial migration, and cytokine production (Figure 1B). Blood pressure was elevated in all MetS groups and all RAS groups develop moderate, but significant stenosis of a similar degree (Table). EVs were detected in the stenotic‐kidney 4 weeks after injection (Figure 2A). Renal volume, RBF, and GFR, which increased in MetS compared to Lean (consistent with hyperfiltration), fell in MetS+RAS, but restored in pigs treated with Lean‐EVs. Lean‐EVs also attenuated tubular injury and renal fibrosis (Figure 2B). Yet, these renoprotective effects were blunted in pigs treated with MetS‐EVs. Conclusion MetS alters the protein cargo of porcine MSC‐derived EVs, selectively packaging specific pro‐inflammatory signatures. Intrarenal delivery of Lean‐EVs attenuated renal injury and fibrosis and improved function in pigs with MetS+RAS, whereas these beneficial effects were blunted in pigs treated with MetS‐EVs. Therefore, our observations suggest that approaches to improve the therapeutic efficacy of autologous MSC‐derived EVs might be useful for patients with MetS+RAS. Support or Funding Information This study was partly supported by the National Institutes of Health grant numbers: DK104273, HL123160, DK102325, and DK106427. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
Jin, Zhaohui , Dixon, Jesse G. , Fiskum, Jack, Yothers, Greg , Allegra, Carmen J. , Haller, Daniel G. , Gramont, Aimery de , Taı̈eb, Julien , Tweleves, Christopher, Sadahiro, Sotaro , Blanke, Charles D. , Tomita, Naohiro , Seitz, Jean‐François, Erlichman, Charles , Yamanaka, Takeharu , Goldberg, Richard M. , George, Thomas J. , Fiskum, Jack M, Yothers, Greg , Haller, Daniel , Kerr, Rachel , Taieb, Julien , Twelves, Christopher , O'Connell, Michael, Saltz, Leonard , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Goldberg, Richard M , George, Thomas J , Shi, Qian , Jin, Zhaohui , Dixon, Jesse G , Parekh, Hiral D. , Sinicrope, Frank A. , Wolmark, Norman , Schmoll, Hans‐Joachim , Kerr, Rachel , Cutsem, Eric Van , Twelves, Chris , O’Connell, Michael J. , Saltz, Leonard B. , Yoshino, Takayuki , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 21, 2021 | Volume: 113 | Issue: 12 | Pages: 1693-1704

10.1093/jnci/djab123 | PMID 34405233 Get It

Abstract Background Colon cancer (CC) incidence in young adults (age 20-49 years), termed early-onset CC (EO-CC), is increasing. Methods Individual patient data on 35 713 subjects with stage III colon cancer from 25 randomized studies in the Adjuvant Colon Cancer ENdpoint database were pooled. The distributions of demographics, clinicopathological features, biomarker status, and outcome data were summarized by age group. Overall survival, disease-free survival, time to recurrence, and survival after recurrence were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for sex, race, body mass index, performance status, disease stage, grade, risk group, number of lymph nodes examined, disease sidedness, and molecular markers. All statistical tests were 2-sided. Results Using a 5% difference between age groups as the clinically meaningful cutoff, patients with stage III EO-CC had similar sex, race, performance status, risk group, tumor sidedness, and T stage compared with patients with late-onset CC (age 50 years and older). EO-CC patients were less likely to be overweight (30.2% vs 36.2%) and more commonly had 12 or more lymph nodes resected (69.5% vs 58.7%). EO-CC tumors were more frequently mismatch repair deficient (16.4% vs 11.5%) and less likely to have BRAFV600E (5.6% vs 14.0%), suggesting a higher rate of Lynch syndrome in EO-CC. Patients with EO-CC had statistically significantly better overall survival (hazard ratio [HR] = 0.81, 95% confidence interval [CI] = 0.74 to 0.89; P &lt; .001), disease-free survival (HR = 0.91, 95% CI = 0.84 to 0.98; P = .01), and survival after recurrence (HR = 0.88, 95% CI = 0.80 to 0.97; P = .008) in the analysis without molecular markers; however, age at onset of CC lost its prognostic value when outcome was adjusted for molecular markers. Conclusion Tumor biology was found to be a more important prognostic factor than age of onset among stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.
The Efficacy of Electrical Baroreflex Activation Therapy is Independent of Peripheral Chemoreceptor Modulation
Thöne, Arvo, Lipp, Axel , Menne, Jan, Reuter, Hannes , Halbach, Marcel , Eckert, Siegfried , Koziolek, Michael , Haarmann, Helge , Diedrich, André , Haller, Hermann , Heusser, Karsten , Beige, Joachim , Hoffmann, Fabian , Wallbach, Manuel , Joyner, Michael J. , Paton, Julian F. R. , Jordan, Jens , Tank, Jens

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.884.6 Get It

Introduction Baroreflex activation through electrical carotid sinus stimulation has been developed for the treatment of patients with arterial hypertension not sufficiently responding to pharmacological therapy. Previous studies suggested that peripheral chemoreflex afferents located in proximity to carotid baroreceptors are tonically active in hypertensive patients and may inhibit baroreflex responses. Therefore, we hypothesized that peripheral chemoreflex activation attenuates the efficacy of electrical carotid sinus stimulation. Methods We screened 35 patients with an implanted electrical carotid sinus stimulator. Of those, 11 patients exhibited a consistent acute depressor response and were included in the study (7 men/4 women, age: 67±8 years, BMI: 31.6±5.2 kg/m 2 , 6±2 antihypertensive drug classes). We assessed responses to electrical baroreflex stimulation during normoxia, isocapnic hypoxia (SpO2: 79.0±1.5%), and hyperoxia (40% end‐tidal O2 fraction) by recording ECG, blood pressure (SBP), ventilation, SpO2, end‐tidal CO2 and O2 fractions, and muscle sympathetic nerve activity (MSNA). Results During normoxia, baroreflex activation reduced SBP from 164±27 to 151±25 mmHg (means±SD, p<0.001), HR from 64±13 to 61±13 bpm (p=0.002), and MSNA from 42±12 to 36±12 bursts/min (p=0.004). Hypoxia increased SBP 8±12 mmHg (p=0.057), HR 10±6 bpm (p<0.001), MSNA 7±7 bursts/min (p=0.031), and ventilation 10±7 l/min (p=0. 002). However, responses to electrical carotid sinus stimulation did not differ between hypoxic and hyperoxic conditions; SBP: −15±7 vs −14±8 mmHg (p=0.938), HR: −2±3 vs −2±2 bpm (p=0.701), and MSNA: −6±4 vs −4±3 bursts/min (p=0.531). Conclusion The main finding of our study is that moderate peripheral chemoreflex activation does not attenuate acute responses to electrical baroreflex activation therapy (BAT) in patients with resistant hypertension. These patients provide insight in human baroreflex physiology and baroreflex‐chemoreflex interactions that could not be gained otherwise. Support or Funding Information Financial support by Boston Scientific Corporation (St. Paul, MN, U.S.A.) This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Mitotic Inheritance of mRNAs encoding Transcription factors in Osteoblastic Cells.
Khani, Farzaneh , Takai, Hideki , Galindo, Mario , Stein, Gary S. , Wijnen, André J. van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.788.12 Get It

Both genomic and non‐genomic mechanisms control the acquisition of specialized cellular phenotypes during development. When differentiated cells enter and exit mitosis, chromosomal condensation prevents gene expression. Post‐mitotic re‐activation of transcription is controlled in part by epigenetic marks on DNA and histones that control chromatin accessibility. However, mRNA molecules also appear to be transferred to progeny cells by either symmetrical or asymmetrical transmission. We have shown that the mRNA for the bone‐related transcription factor Runx2 mRNAs is elevated in the G2 phase of the cell cycle, but not translated in osteoblasts. This observation suggests that Runx2 protein is translationally rather than transcriptionally controlled after mitosis to maintain the phenotypic identity of osteoblasts. We used RNA‐seq expression profiling to assess whether there are other gene regulatory factors that are transmitted through mitosis. Our main results show that mRNAs for transcription factors are typically depleted during mitosis. For example, while Runx2 mRNA is retained in mitotic cells, expression of the closely related genes Runx1 and Runx3 is reduced. Strikingly, expression of Osterix/Sp7 and MEF2C, two transcription factors known to cooperate biologically with Runx2 in promoting the osteoblastic state, is selectively retained in mitotic cells. Our data suggest that selective somatic transmission of mRNAs for transcription factors in osteoblasts may be a general mechanism by which cells maintain their identity during cell division in skeletal development. Support or Funding Information NIH R01 AR049069 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Synergistic regulation of the Runx2 P1 promoter in mesenchymal cells by a conserved HLH box and purine‐rich elements (GAY motifs)
Hassan, Mohammad Q., Hawse, John R. , Spelsberg, Thomas C., Stein, Janet L. , Lian, Jane B. , Zhang, Ying , Montecino, Martı́n , Wijnen, André J. van , Stein, Gary S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.782.17 Get It

Transcriptional control of Runx2 gene expression through two alternative promoters (P1 and P2) is critical for the execution of its function as an osteogenic cell fate determining factor. Using genomic DNaseI footprinting and in vivo DNA binding assays, we identified a helix‐loop‐helix (HLH) motif that overlaps with a Runx motif in the P1 promoter. The HLH mutation decreases P1 transcription 10‐fold in mesenchymal cells, while mutation of the Runx site enhances transcription 2 fold. Although the HLH element is not cell‐type specific, its function may depend on promoter context. Promoter deletion analysis shows that a GA‐rich region (−200 to −128) positively regulates Runx2 P1 transcription and synergizes with the HLH motif. Examination of the −200/−128 region reveals two tandemly repeated GA‐rich elements (GAY motifs) that each contain recognition motifs for purine‐rich DNA binding factors (i.e., SP1 and KLF10/TGFâ Inducible Factor [TIEG]). Forced expression of SP1 or TIEG modulates Runx2 P1 promoter activity through the GAY motifs. Taken together, our data suggest that the Runx2 gene transcription is regulated by synergistic interactions at multiple conserved composite promoter elements to control Runx2 expression and skeletal development.
Lamin A/C Is Dispensable to Mechanical Repression of Adipogenesis
Goelzer, Matthew , Dudakovic, Amel , Olcum, Melis , Sen, Buer , Özçivici, Engin , Rubin, Janet , Wijnen, André J. van , Uzer, Gunes , van Wijnen, Andre J , Dudakovic, Amel

Mayo Clinic

International Journal of Molecular Sciences | June 20, 2021 | Volume: 22 | Issue: 12 | Pages: 6580

10.3390/ijms22126580 | PMID 34205295 Get It

Mesenchymal stem cells (MSCs) maintain the musculoskeletal system by differentiating into multiple lineages, including osteoblasts and adipocytes. Mechanical signals, including strain and low-intensity vibration (LIV), are important regulators of MSC differentiation via control exerted through the cell structure. Lamin A/C is a protein vital to the nuclear architecture that supports chromatin organization and differentiation and contributes to the mechanical integrity of the nucleus. We investigated whether lamin A/C and mechanoresponsiveness are functionally coupled during adipogenesis in MSCs. siRNA depletion of lamin A/C increased the nuclear area, height, and volume and decreased the circularity and stiffness. Lamin A/C depletion significantly decreased markers of adipogenesis (adiponectin, cellular lipid content) as did LIV treatment despite depletion of lamin A/C. Phosphorylation of focal adhesions in response to mechanical challenge was also preserved during loss of lamin A/C. RNA-seq showed no major adipogenic transcriptome changes resulting from LIV treatment, suggesting that LIV regulation of adipogenesis may not occur at the transcriptional level. We observed that during both lamin A/C depletion and LIV, interferon signaling was downregulated, suggesting potentially shared regulatory mechanism elements that could regulate protein translation. We conclude that the mechanoregulation of adipogenesis and the mechanical activation of focal adhesions function independently from those of lamin A/C.
FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL
Kopečková, Kateřina , Burgués, Juan Miguel Bergua, Pichler, P. , Klöpfer, Pia, Brackertz, Bettina, Lohrmann, E., Lahiry, Anirban , Shah, Neha , Brugger, Wolfram, Burke, John M. , Nowakowski, Grzegorz S. , Belada, David , André, Marc , Persona, Ernesto Pérez

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.149_2880 Get It

Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial
Kudva, Yogish C. , Laffel, Lori M. , Brown, Sue A. , Raghinaru, Dan, Pinsker, Jordan E. , Ekhlaspour, Laya , Messer, Laurel H. , Kovatchev, Boris , Lum, John W. , Gonder‐Frederick, Linda , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Buckingham, Bruce A. , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Eggerman, Thomas L., Messer, Laurel H , Lum, John , Forlenza, Gregory P , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Beck, Roy W. , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Doyle, Francis J. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | June 11, 2021 | Volume: 23 | Issue: 10 | Pages: 673-683

10.1089/dia.2021.0089 | PMID 34115959 Get It

Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC ( N = 112) versus SAP ( N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.